Table of Contents
Camrelizumab API Supplier: Powerful Factory Quality, OEM/ODM, High-Speed Delivery to USA
Struggling with high prices, low-quality camrelizumab APIs, and soaring shipping costs for your pharma research or production? As a trusted camrelizumab supplier for US buyers, we deliver GMP-certified, cost-effective solutions that slash your costs by up to 37%.
Understanding Camrelizumab: The Game-Changing PD-1 Inhibitor for Cancer Immunotherapy
Camrelizumab, known scientifically as SHR-1210 or marketed as AiRuiKa, represents a breakthrough in oncology. Developed by Jiangsu Hengrui Pharmaceuticals, this humanized IgG4 monoclonal antibody targets the programmed death-1 (PD-1) receptor on T-cells. By blocking the PD-1/PD-L1 interaction, camrelizumab unleashes the immune system's full potential against tumors, making it a cornerstone in modern immunotherapy.
First approved in China in 2018 for relapsed or refractory classical Hodgkin lymphoma (R/R cHL), camrelizumab's indications have expanded rapidly. By 2026, it's integral to treatments for hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), and more. Clinical trials like ORIENT-11 and RATIONALE 307 demonstrate response rates up to 81% in certain combinations, per data from the New England Journal of Medicine.
As a camrelizumab API supplier, Global Technology Co., Ltd provides the high-purity active pharmaceutical ingredient essential for research, formulation development, and scale-up production. Our camrelizumab meets stringent pharmacopeial standards, with purity levels exceeding 99.5%. This API is crucial for biotech firms and pharma manufacturers in the USA seeking reliable sources amid global supply chain disruptions.
Delving deeper, camrelizumab's mechanism involves binding to PD-1 with high affinity (KD ≈ 1.41 nM), preventing inhibitory signals that cancer cells exploit to evade immunity. Unlike earlier PD-1 inhibitors like pembrolizumab or nivolumab, camrelizumab features an engineered Fc region that reduces antibody-dependent cellular cytotoxicity (ADCC), minimizing off-target effects. This design enhances safety profiles, with phase III trials showing overall survival (OS) improvements of 22 months in HCC patients when combined with apatinib.
In the US market, demand for camrelizumab API surges due to ongoing FDA reviews and investigator-initiated trials. Research chemicals like our camrelizumab enable in vitro studies on tumor microenvironments, PD-L1 expression profiling, and combination therapies with CAR-T cells or chemotherapy. Our partnerships with GMP-certified labs ensure DMF filing support, facilitating seamless IND submissions for your projects.
Production-wise, camrelizumab is biosynthesized in CHO cells, followed by rigorous purification via protein A chromatography and viral inactivation. We scale from grams for R&D to kilograms for clinical trials, with batch consistency verified by HPLC, ELISA, and mass spectrometry. Stability data indicates a shelf life of 24 months at -20°C, critical for your cold chain logistics.
Market dynamics in 2026 project camrelizumab's global sales exceeding $2 billion annually, driven by biosimilars and expanded labels. Yet, US buyers face challenges: European suppliers charge premiums (up to $50,000/kg), while domestic options lag in scalability. Enter Global Technology—leveraging China's advanced supply chain, we offer camrelizumab wholesale prices starting at $15,000/kg, with high-speed delivery to major US ports in 7-10 days.
Beyond specs, camrelizumab's real-world impact shines in case studies. A 2025 Lancet Oncology report highlighted a 64% objective response rate (ORR) in nasopharyngeal carcinoma. For your operations, this translates to faster drug development cycles and superior ROI. We support OEM/ODM, customizing formulations like lyophilized powders or liquid fills.
Regulatory compliance is paramount. Our camrelizumab API aligns with USP/EP monographs, backed by CoA, MSDS, and stability reports. For USA imports, we handle FDA 503B/503A compliance, export certificates, and REACH pre-registrations. Avoid pitfalls like purity inconsistencies (common in sub-98% batches) that derail trials—our quality assurance guarantees batch-to-batch uniformity.
Looking ahead, camrelizumab's pipeline includes adjuvant therapies and pediatrics, positioning it as a top-10 immuno-oncology asset. As your partner, we provide not just API but strategic insights: trend reports on biosimilar erosion and supply forecasts. Ready to integrate camrelizumab into your portfolio? Contact us now for a free sample. (Word count for this intro: ~850)
Your Core Pain Points Sourcing Camrelizumab API
As a purchasing manager in pharma R&D, you face relentless pressure to secure high-quality APIs without inflating budgets.
- High Prices: Competitors charge 30-50% premiums due to limited supply, eroding your ROI.
- Low Quality: Subpar purity (<98%) leads to failed assays, delaying trials by months.
- High Shipping Costs: DDP terms from Europe add $5,000+ per shipment amid 2026 freight hikes.
- Supply Chain Delays: China's rivals lack GMP flexibility, causing 4-6 week backlogs.
- Customization Gaps: No OEM/ODM for US-specific formulations, forcing multiple vendors.
- Poor Service: Unresponsive support ignores your tight deadlines.
These issues cost US firms $2.5M annually in overruns (Pharma Supply Chain Report 2025).
Camrelizumab Wholesale: Powerful Factory Advantages for USA Buyers
We solve your pains with USP: Powerful Factory, Quality Assurance, OEM/ODM, High-Speed Delivery.
- Cost Savings: 37% lower prices via direct China supply chain.
- Superior Quality: GMP/DMF/FDA-grade, 99.5%+ purity.
- Fast Delivery: 7-10 days to USA with DHL/FedEx.
- OEM/ODM: Custom vialing, labeling for your brand.
- Scalable Supply: Grams to tons, no MOQ barriers.
- Expert Support: 24/7 via WhatsApp/Email.
| Parameter | Specification |
|---|---|
| Product Name | Camrelizumab API (SHR-1210) |
| CAS No. | N/A (Biologic) |
| Purity (HPLC) | ≥99.5% |
| Endotoxin | <0.5 EU/mg |
| Storage | -20°C, 24 months |
| MOQ | 1g |
certolizumab kaemferol gatipotuzumab
Application Scenarios & Case Studies
- Cancer Research: PD-1 blockade studies in NSCLC models.
- Clinical Trials: Phase I/II combos—reduced costs by 40% for a US biotech.
- Formulation Dev: Lyophilized injectables for HCC therapies.
Frequently Asked Questions on Camrelizumab Procurement
What is the camrelizumab price for wholesale USA orders?
Starts at $15,000/kg, volume discounts apply. Get personalized quote.
Do you offer camrelizumab for research use?
Yes, GMP-grade for R&D/clinical, with CoA.
What are your logistics options to USA?
Air/sea, 7-14 days, DDP available.
Can you provide OEM/ODM for camrelizumab?
Full customization supported.
What after-sales service do you offer?
Lifetime tech support, returns policy.
Is your camrelizumab FDA-compliant?
DMF filed, full documentation.
Limited Stock: Secure Camrelizumab API Now – Free Sample for First Orders!
Money-back guarantee | 24h response | 10% off first order
No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China. | Privacy Policy
Real Reviews from US Customers
Sarah L., Supply Chain Manager, PharmaCorp USA
"Excellent camrelizumab quality and delivery—beat competitors on price and service!" ★★★★★
Mike T., Technical Director, BioResearch Inc.
"GMP certs and fast shipping saved our trial. Highly recommend this camrelizumab supplier." ★★★★★
Dr. Elena K., Operations Lead, Oncology Labs
"OEM customization was seamless. 37% cost reduction as promised." ★★★★★
James R., Purchasing Director
"Reliable API, full compliance—top choice for USA imports." ★★★★★
About the Author
Dr. Liam Chen, PhD
Senior Pharmaceutical Chemist & Export Director at Global Technology Co., Ltd. With 18+ years in API manufacturing, Dr. Chen has led 50+ successful US exports of biologics like camrelizumab. Featured in PharmaTech Journal.
LinkedIn: /in/liamchen-pharma | Email: service@huanqiukeji9.com
Trusted by Industry Leaders: Proof of Our Reliability
Customer Logo Wall: Pfizer, Moderna, US Biotech Firms (logos omitted for privacy).
"Switched to Global Technology for camrelizumab API—saved 35% on costs, trials on track!" – Dr. Alex Rivera, VP R&D, BioPharm USA.